Comparative evaluation of platelet count and antimicrobial efficacy of injectable platelet-rich fibrin with other platelet concentrates: An in vitro study

Prerna Ashok Karde, Kunal Sunder Sethi, Swapna Arunkumar Mahale, Smita Uday Khedkar, Agraja Ganpat Patil, Chaitanya Pradeep Joshi, Prerna Ashok Karde, Kunal Sunder Sethi, Swapna Arunkumar Mahale, Smita Uday Khedkar, Agraja Ganpat Patil, Chaitanya Pradeep Joshi

Abstract

Background: Platelet concentrates are used in various medical procedures to promote soft- and hard-tissue regeneration. In recent times, their antimicrobial efficacy is also explored. However, various platelet concentrates have evolved which differ in the centrifugation protocols. One such recently introduced platelet concentrate is injectable platelet-rich fibrin (i-PRF) concentrate. Hence, the aim was to evaluate the antimicrobial property, and platelet count of i-PRF in comparison to other platelet concentrates, i.e., PRF, platelet-rich plasma (PRP), and control (whole blood).

Materials and methods: Blood samples were obtained from 10 chronic generalized marginal gingivitis patients. Platelet concentrates were prepared using standardized centrifugation protocol. Platelet count was evaluated by manual counting method using smear preparation of each sample. Subsequently, antimicrobial activity against oral bacteria was examined on blood agar using disc diffusion method to quantify the inhibitory effects.

Results: Statistical significance was analyzed by one-way analysis of variance (ANOVA). P <0.05 was considered statistically significant. Mean zone of inhibition around i-PRF (P < 0.01) and PRF (P < 0.05) showed statistical significance. Although a distinct zone of inhibition was seen with PRP, it was not statistically significant (P > 0.05). i-PRF showed statistically significant difference (P < 0.001) in platelet count when compared to control. It was also significant when compared to PRP (P < 0.01), PRF (P < 0.001).

Conclusion: i-PRF has maximum antimicrobial efficacy and higher platelet count in comparison to other platelet concentrates, thereby indicating to have a better regenerative potential then others.

Keywords: Antimicrobial; periodontitis; platelet counts; platelet-rich plasma.

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Platelet concentrate samples obtained after centrifugation protocol. (a) Injectable platelet-rich fibrin; (b) platelet-rich fibrin; (c) platelet-rich plasma; (d) control
Figure 2
Figure 2
Smear preparation of platelet concentrates observed under ×100 oil immersion. Arrows indicate platelets. (a) Control; (b) injectable platelet-rich fibrin; (c) platelet-rich plasma; (d) platelet-rich fibrin
Figure 3
Figure 3
Zone of inhibition using agar well diffusion method for injectable platelet-rich fibrin, Platelet-rich plasma, platelet-rich fibrin, control

References

    1. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part III: Leucocyte activation: A new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e51–5.
    1. El-Sharkawy H, Kantarci A, Deady J, Hasturk H, Liu H, Alshahat M, et al. Platelet-rich plasma: Growth factors and pro- and anti-inflammatory properties. J Periodontol. 2007;78:661–9.
    1. Del Fabbro M, Ceresoli V, Lolato A, Taschieri S. Effect of platelet concentrate on quality of life after periradicular surgery: A randomized clinical study. J Endod. 2012;38:733–9.
    1. Choukroun J. Advanced PRF & i-PRF: Platelet concentrates or blood concentrates? J Periodontal Med Clin Pract. 2014;1:3.
    1. Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandalam U, Zhang Y, Ghanaati S, et al. Injectable platelet rich fibrin (i-PRF): Opportunities in regenerative dentistry? Clin Oral Investig. 2017;2:1–9.
    1. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part I: Technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:e37–44.
    1. Malok M, Titchener EH, Bridgers C, Lee BY, Bamberg R. Comparison of two platelet count estimation methodologies for peripheral blood smears. Clin Lab Sci. 2007;20:154–60.
    1. Bajpai R, Rajak C, Poonia M. Platelet estimation by peripheral smear: Reliable, rapid, cost-effective method to assess degree of thrombocytopenia. Int J Med Sci Res Pract. 2015;2:90–3.
    1. Aggarwal A, Singhal N. Evaluation of content and distribution of platelets in platelet rich fibrin at various centrifugation time periods: A light microscopic study. Int J Dent Med Res. 2015;1:61–4.
    1. Pradeep AR, Shetty SK, Garg G, Pai S. Clinical effectiveness of autologous platelet-rich plasma and Peptide-enhanced bone graft in the treatment of intrabony defects. J Periodontol. 2009;80:62–71.
    1. Preeja C, Arun S. Platelet-rich fibrin: Its role in periodontal regeneration. Saudi J Dent Res. 2014;5:117–22.
    1. Ghanaati S, Booms P, Orlowska A, Kubesch A, Lorenz J, Rutkowski J, et al. Advanced platelet-rich fibrin: A new concept for cell-based tissue engineering by means of inflammatory cells. J Oral Implantol. 2014;40:679–89.
    1. Lucarelli E, Beretta R, Dozza B, Tazzari PL, O'Connel SM, Ricci F, et al. A recently developed bifacial platelet-rich fibrin matrix. Eur Cell Mater. 2010;20:13–23.
    1. Suchetha A, Lakshmi P, Bhat D, Mundinamane DB, Soorya KV, Bharwani GA. Platelet concentration in platelet concentrates and periodontal regeneration-unscrambling the ambiguity. Contemp Clin Dent. 2015;6:510–6.
    1. Badade PS, Mahale SA, Panjwani AA, Vaidya PD, Warang AD. Antimicrobial effect of platelet-rich plasma and platelet-rich fibrin. Indian J Dent Res. 2016;27:300–4.
    1. Joshi CP, Patil AG, Karde PA, Khedkar SU, Mahale SA, Dani NH, et al. Autologous platelet rich fibrin as a potential antiperiopathogenic agent: An in-vitro study. Int J Periodontol Implantol. 2016;1:50–4.
    1. Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis. 1997;25:951–68.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi